Renal cell carcinoma before and after Sunitinib therapy. Morphological and molecular changes

R Doshi, M O'Donnel, M Bex, L Beltran, A Sahdev, J Peters, David J Harrison, Grant Stewart, T Powles, D Berney

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Abstract

The use of tyrosine kinase inhibitors (TKI) has transformed the treatment of clear cell renal cell carcinoma (ccRCC). We have previously published 48 patients with metastatic ccRCC, treated with Sunitinib for 16 weeks and then given a nephrectomy, if feasable. Pretreatment biopsy material was taken for diagnostic purposes. Little translational work on this treated tissue is available. Changes in morphology after TKI therapy are not well documented and the possibility of a ‘regression score’ in treated cancers may aid further therapy.
Original languageEnglish
Title of host publication101st Annual Meeting Abstracts, Vancouver Convention Centre, Vancouver, British Columbia, Canada, March 17 – March 23, 2012
PublisherLaboratory investigation; a journal of technical methods and pathology
Pages201A-201A
Volume92
DOIs
Publication statusPublished - 1 Feb 2012

Fingerprint

Dive into the research topics of 'Renal cell carcinoma before and after Sunitinib therapy. Morphological and molecular changes'. Together they form a unique fingerprint.

Cite this